In a report issued on May 15, Sam Poser from Williams Trading maintained a Buy rating on Shoe Carnival (SCVL – Research Report), with a price target of $47.00. The company’s shares closed last Wednesday at $26.49, close to its 52-week low of $25.80.
According to TipRanks.com, Poser is a 5-star analyst with an average return of 18.7% and a 47.3% success rate. Poser covers the Consumer Goods sector, focusing on stocks such as Canada Goose Holdings, Dick’s Sporting Goods, and Wolverine World Wide.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Shoe Carnival with a $47.00 average price target.
The company has a one-year high of $46.21 and a one-year low of $25.80. Currently, Shoe Carnival has an average volume of 344.1K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SCVL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Shoe Carnival, Inc. engages in the retail of footwear products. It offers casual and athletic footwear for men, women, and children under the Skechers, Clarks, Adidas, Crocs, New Balance, Converse, Roxy, Nike, Vans, Madden Girl, Sperry, Rampage, Keds, PUMA, Timberland, Koolaburra, Jellypop, and ASICS brands. The company was founded in 1978 and is headquartered in Evansville, IN.
Read More on SCVL:
- Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Enanta Pharmaceuticals (ENTA) and InflaRx (IFRX)
- Wall Street Analysts Are Bullish on Top Technology Picks
- Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Altria Group (MO), Foot Locker (FL) and Lowe’s (LOW)
- SVB Securities Thinks Graphite Bio’s Stock is Going to Recover
- SVB Securities Thinks Molecular Partners’ Stock is Going to Recover